DelveInsight’s “Psychosis in Parkinson’s and Alzheimer’s Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Psychosis in Parkinson’s and Alzheimer’s Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Psychosis in Parkinson’s and Alzheimer’s Disease drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Psychosis in Parkinson’s and Alzheimer’s Disease treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Psychosis in Parkinson’s and Alzheimer’s Disease: An Overview
According to the National Institute of Mental Health (NIMH), psychosis is a collection of symptoms that affect the mind, where there has been some loss of contact with reality. During an episode of psychosis, individuals’ thoughts and perceptions are disrupted, which leads to difficulty recognizing what is real and what is unreal.
Parkinson’s disease psychosis (PDP) is a common phenomenon in PD patients associated with high morbidity and mortality, caused due to abnormalities in dopamine, serotonin, and glutamate neurotransmission due to the deposition of Lewy bodies in the brain.
AD, a neurodegenerative disorder that destroys memory and other important mental functions in an individual, is commonly termed dementia worldwide. Alzheimer’s disease psychosis (ADP), a typical occurrence in AD patients, is caused due to increased excitatory neuron sensitivity and post-transcriptional mechanisms that change synaptic protein in the brain.
Both exogenous (for example, drugs) and endogenous (related to the disease process) factors contribute to the development of psychosis in Parkinson’s disease (PD) and Alzheimer’s disease (AD). Several risk factors associated with the disease include old age, sleep disturbances, long-duration of neurodegenerative disorder, depression, cognitive impairment, and visual disorders.
The primary aim of the treatment is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms in PDP and ADP patients. Atypical antipsychotics include clozapine, quetiapine, olanzapine, risperidone, and aripiprazole are used. Clozapine is well-studied and is considered the “gold standard” treatment in psychosis of PD.
Psychosis in Parkinson’s and Alzheimer’s Disease Market Key Facts
The market size of psychosis in Parkinson’s and Alzheimer’s Disease in the US will increase at a CAGR of 15.6% due to increasing awareness of the disease and the launch of the emerging therapy.
Among EU4 and the UK countries, Germany accounted for the maximum market size of psychosis in Parkinson’s and Alzheimer’s Disease in 2022, while the UK occupied the bottom of the ladder.
The total number of diagnosed prevalent cases of psychosis in Parkinson’s and Alzheimer’s Disease in the United States was around 2,308,528 in 2022. Approximately 80% of these cases were due to Alzheimer’s disease psychosis, while Parkinson’s disease psychosis was attributed to only 20% of the total diagnosed psychosis cases.
In EU4 and the UK, patients diagnosed with Alzheimer’s disease are higher in number than Parkinson’s disease. In 2022, there were around 4,942,376 diagnosed prevalent cases of Alzheimer’s disease, while diagnosed prevalent cases of Parkinson’s disease accounted for 1,170,838 cases. These numbers are expected to rise during the study period.
According to DelveInsight estimates, in EU4 and the UK, there were nearly 643,961 males and 526,877 females diagnosed with Parkinson’s disease, and approximately 1,454,541 males and 3,487,835 females diagnosed with Alzheimer’s disease in 2022, which are projected to increase during the forecast period.
Psychosis in Parkinson’s and Alzheimer’s Disease Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Psychosis in Parkinson’s and Alzheimer’s Disease pipeline therapies. It also thoroughly assesses the Psychosis in Parkinson’s and Alzheimer’s Disease market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Psychosis in Parkinson’s and Alzheimer’s Disease drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Psychosis in Parkinson’s and Alzheimer’s Disease epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Psychosis in Parkinson’s and Alzheimer’s Disease epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Psychosis in Parkinson’s and Alzheimer’s Disease Epidemiology, Segmented as –
Diagnosed prevalent cases of Parkinson’s and Alzheimer’s Disease
Gender-specific diagnosed prevalent cases of Parkinson’s and Alzheimer’s Disease
Age-specific diagnosed prevalent cases of Parkinson’s and Alzheimer’s Disease
Diagnosed prevalent cases of psychosis in Parkinson’s and Alzheimer’s Disease
Psychosis in Parkinson’s and Alzheimer’s Disease Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Psychosis in Parkinson’s and Alzheimer’s Disease market or expected to be launched during the study period. The analysis covers the Psychosis in Parkinson’s and Alzheimer’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Psychosis in Parkinson’s and Alzheimer’s Disease drugs based on their sale and market share.
The report also covers the Psychosis in Parkinson’s and Alzheimer’s Disease pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Psychosis in Parkinson’s and Alzheimer’s Disease companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Psychosis in Parkinson’s and Alzheimer’s Disease Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market
Psychosis in Parkinson’s and Alzheimer’s Disease Therapeutics Analysis
The current treatment of Psychosis in PD and AD involves nonpharmacological and pharmacological approaches. The primary aim of the treatment is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms. The use of typical and atypical antipsychotics is the first-line treatment (e.g., aripiprazole, clozapine, quetiapine, etc.). However, atypical antipsychotics are often considered in the initial therapy, which reduces the risk of later deterioration in patients. Apart from antipsychotics, 5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), or other antidepressants are also used.
Behavioral and psychological symptoms of dementia (BPSD), anxiety, psychosis, agitation, aggression, sleep disturbances, and others associated with psychosis in PD and AD are controlled using cognitive behavioral therapy (CBT), reasoning, and rehabilitation.
Psychosis in Parkinson’s and Alzheimer’s Disease Companies Actively Working in the Therapeutics Market Include
Sunovion Pharmaceuticals
Karuna Therapeutics
Vanda Pharmaceuticals
Suven Life Sciences
Enterin
Intra-Cellular Therapies
Merck Sharp & Dohme
And Many Others
Emerging and Marketed Psychosis in Parkinson’s and Alzheimer’s Disease Therapies Covered in the Report Include:
Ulotaront (SEP-363856): Sunovion Pharmaceuticals
KarXT (xanomeline-trospium): Karuna Therapeutics
FANAPT: Vanda Pharmaceuticals
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Psychosis in Parkinson’s and Alzheimer’s Disease Competitive Intelligence Analysis
4. Psychosis in Parkinson’s and Alzheimer’s Disease Market Overview at a Glance
5. Psychosis in Parkinson’s and Alzheimer’s Disease Disease Background and Overview
6. Psychosis in Parkinson’s and Alzheimer’s Disease Patient Journey
7. Psychosis in Parkinson’s and Alzheimer’s Disease Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Psychosis in Parkinson’s and Alzheimer’s Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Psychosis in Parkinson’s and Alzheimer’s Disease Unmet Needs
10. Key Endpoints of Psychosis in Parkinson’s and Alzheimer’s Disease Treatment
11. Psychosis in Parkinson’s and Alzheimer’s Disease Marketed Therapies
12. Psychosis in Parkinson’s and Alzheimer’s Disease Emerging Drugs and Latest Therapeutic Advances
13. Psychosis in Parkinson’s and Alzheimer’s Disease Seven Major Market Analysis
14. Attribute Analysis
15. Psychosis in Parkinson’s and Alzheimer’s Disease Market Outlook (In US, EU5, and Japan)
16. Psychosis in Parkinson’s and Alzheimer’s Disease Companies Active in the Market
17. Psychosis in Parkinson’s and Alzheimer’s Disease Access and Reimbursement Overview
18. KOL Views on the Psychosis in Parkinson’s and Alzheimer’s Disease Market
19. Psychosis in Parkinson’s and Alzheimer’s Disease Market Drivers
20. Psychosis in Parkinson’s and Alzheimer’s Disease Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Erythropoietic Protoporphyria Market
“Erythropoietic Protoporphyria Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Erythropoietic Protoporphyria market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Erythropoietic Protoporphyria market.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailAddress:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/oncology
